Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Leads Rebound In Rx Stocks; Upbeat Finish To Historic Bad Year

Executive Summary

Merck's fourth quarter rebound suggests that Wall Street may be looking on the bright side for pharmaceutical stocks at last

You may also be interested in...

Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March

Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative

Medicare Rx Positioning For 2003: Merck Prepares Investors For Benefit

Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress

Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”

Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts